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introduction: Computed tomography (CT), combined positron emitted tomography 
and CT (PET/CT), and magnetic resonance imaging (MRI) are commonly used in head 
and neck radiation planning. Hybrid PET/MRI has garnered attention for potential added 
value in cancer staging and treatment planning. Herein, we compare PET/MRI vs. plan-
ning CT for head and neck cancer gross tumor volume (GTV) delineation.
Material and methods: We prospectively enrolled patients with head and neck cancer 
treated with definitive chemoradiation to 60–70 Gy using IMRT. We performed pretreat-
ment contrast-enhanced planning CT and gadolinium-enhanced PET/MRI. Primary and 
nodal volumes were delineated on planning CT (GTV-CT) prospectively before treatment 
and PET/MRI (GTV-PET/MRI) retrospectively after treatment. GTV-PET/MRI was com-
pared to GTV-CT using separate rigid registrations for each tumor volume. The Dice 
similarity coefficient (DSC) metric evaluating spatial overlap and modified Hausdorff dis-
tance (mHD) evaluating mean orthogonal distance difference were calculated. Minimum 
dose to 95% of GTVs (D95) was compared.
results: Eleven patients were evaluable (10 oropharynx, 1 larynx). Nine patients had 
evaluable primary tumor GTVs and seven patients had evaluable nodal GTVs. Mean 
primary GTV-CT and GTV-PET/MRI size were 13.2 and 14.3 cc, with mean intersection 
8.7 cc, DSC 0.63, and mHD 1.6 mm. D95 was 65.3 Gy for primary GTV-CT vs. 65.2 Gy 
for primary GTV-PET/MRI. Mean nodal GTV-CT and GTV-PET/MRI size were 19.0 and 
23.0 cc, with mean intersection 14.4 cc, DSC 0.69, and mHD 2.3 mm. D95 was 62.3 Gy 
for both nodal GTV-CT and GTV-PET/MRI.
conclusion: In this series of patients with head and neck (primarily oropharynx) cancer, 
PET/MRI and CT-GTVs had similar volumes (though there were individual cases with 
larger differences) with overall small discrepancies in spatial overlap, small mean orthog-
onal distance differences, and similar radiation doses.
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inTrODUcTiOn
Head and neck radiation oncologists routinely utilize computed 
tomography (CT), combined positron emitted tomography and 
CT (PET/CT), and magnetic resonance imaging (MRI) for stag-
ing, treatment planning, and assessment of disease response. PET/
CT has been shown to be superior to CT alone in staging head 
and neck cancer, with better sensitivity for nodal disease as well 
as distant metastases (1–3). However, MRI has potential advan-
tages over CT, including detection of perineural spread, vascular 
involvement, and invasion of adjacent structures, as well as better 
soft tissue contrast (4–8). In addition, diffusion-weighted MRI 
imaging has been investigated as a method of increasing specific-
ity for detection of nodal metastases and may add further benefit 
(9). The advantages of both PET/CT and MRI over CT alone have 
led to research into the role of hybrid PET/MRI imaging. This 
technology allows for simultaneous data acquisition resulting 
in optimal spatial and temporal co-registration of structural, 
functional, and molecular image data.
Combined positron emitted tomography and CT images are 
commonly utilized for delineation of the gross target volume 
(GTV) during radiotherapy treatment planning either with the 
use of dedicated PET/CT simulators or by registration to plan-
ning CT scan. However, advantages of MRI such as those dis-
cussed above could theoretically improve the accuracy of tumor 
delineation with PET/MRI vs. PET/CT. Furthermore, PET/CT 
images are acquired using sequential image registration, which 
may introduce spatial errors (though this may be mitigated with 
mask immobilization). In contrast, PET and MRI sequences are 
acquired simultaneously, which may reduce registration error 
(though ultimately this benefit may be limited by the need for a 
subsequent fusion to a treatment planning CT) (10). Nonetheless, 
the better soft tissue contrast of MRI combined with simultane-
ously acquired metabolic PET data may improve the accuracy 
and precision of GTV delineation, which could translate into 
changes in the clinical target volume (CTV) and/or affect the 
size of subsequent margins due to heightened confidence. These 
changes could have clinical implications for patients with regards 
to both disease control and treatment toxicity.
Previous studies have shown that use of PET/CT for treat-
ment planning can sometimes alter GTV contours (11–13). 
Furthermore, PET/CT may more broadly impact treatment 
decisions, such as coverage of regional lymph nodes due to the 
increased sensitivity for nodal and distant disease. There have 
been several reports on the use of hybrid PET/MRI in the staging 
and posttreatment surveillance of head and neck cancer (14–19). 
However, there are no reports to our knowledge that have exam-
ined the usefulness of PET/MRI for radiation treatment planning 
for head and neck cancer. Delineating the primary tumor dur-
ing head and neck radiation planning is challenging and relies 
on both physical exam and imaging findings, especially in the 
oropharynx, where borders between tumor and surrounding soft 
tissue may be indistinct. Therefore, we hypothesized that PET/
MRI could improve contour accuracy in this setting. The purpose 
of this study is to assess differences in GTV delineation using 
hybrid PET/MRI vs. CT and to analyze CT-planned radiation 
dose coverage of the PET/MRI-delineated GTV.
MaTerials anD MeThODs
Patient Population
We prospectively enrolled patients aged 18 years or higher with 
squamous cell carcinoma of the pharynx, larynx, or oral cavity 
who were treated definitively with radiation plus or minus concur-
rent chemotherapy with curative intent. Patients were excluded if 
they had an allergy to gadolinium, creatinine clearance <60 ml/
min, were claustrophobic, or had an implanted pacemaker or 
other metallic devices. This study was carried out in accordance 
with the recommendations of the University of North Carolina 
Institutional Review Board with written informed consent from 
all subjects. All subjects gave written informed consent in accord-
ance with the Declaration of Helsinki. The protocol was approved 
by the University of North Carolina Institutional Review Board 
(Lineberger Comprehensive Cancer Center 1020, IRB Study 
#10-1451).
Pretreatment imaging
Patients received treatment-planning CT simulation and PET/
MRI scans 1–2 weeks prior to initiating radiotherapy. Treatment 
planning CT scans were obtained using a Philips Brilliance Big 
Bore Oncology CT scanner using intravenous iodinated contrast 
and with slice thickness ≤3 mm. Patients were immobilized using 
an aquaplast U-frame mask form fitted on the patient’s face and 
locked on to the table.
Positron emitted tomography/MRI scans were obtained after 
a 6-h fasting period. Patients received 10  mCi of intravenous 
18F-FDG, 40–45 min prior to image acquisition. PET/MRI scans 
were conducted using a 3T Siemens Biograph mMR scanner. 
After acquiring localization images, MR attenuation images were 
acquired using the Dixon approach with a coronal 2-point 3D 
T1-weighted volumetric interpolated breath hold examination 
(VIBE) Dixon sequence [repetition time (TR) =  3.6  ms, echo 
time (TE) = 1.23 and 2.46 ms, 10° flip angle, 192 × 121 matrix, 
500 mm × 328 mm field of view (FOV), 3.12 mm slice thickness, 
20% interslice gap, one signal average, integrated parallel acquisi-
tion technique (iPAT) factor 2, acquisition time 19 s].
For the earlier patients recruited for the study, the anatomic 
MR imaging included pre- and postcontrast axial T1-weighted 
fast low angle shot (FLASH) images (TR = 310 ms, TE = 2.46 ms, 
76° flip angle, 320 × 256 matrix, 230 mm × 230 mm FOV, 3 mm 
slice thickness with a 20% interslice gap, three signal averages, 
acquisition time 4  min) and fat-suppressed turbo spin echo 
T2-weighted images (TR = 8,260 ms, TE = 100 ms, 150° flip angle, 
512 × 256 matrix, 230 mm × 230 mm FOV, 3 mm slice thickness 
with a 20% gap, two signal averages, iPAT factor 2, acquisition 
time 2  min 55  s). For patients enrolled later in the study, the 
T1 FLASH acquisitions were replaced with a fat-suppressed 
T1-weighted VIBE sequences (TR =  4.8  ms, TE =  2.18 ms, 9° 
flip angle, 256 × 256 matrix, 240 mm × 217 mm FOV, 0.9 mm 
slice thickness with a 20% gap, two signal averages, iPAT factor 2, 
acquisition time 6 min 55 s) Post-contrast images were obtained 
following intravenous injection of 0.2 mmol/kg of gadopentetate 
dimeglumine. Total “scan time” ranged from 30 to 45 min. PET/
MRI scans were not obtained with immobilization in the treat-
ment position.
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gTV-cT Delineation and Treatment
Contours for primary and nodal tumor volumes were drawn 
separately. Primary and nodal gross tumor volumes were deline-
ated by the treating radiation oncologist on the contrast-enhanced 
treatment planning CT (GTV-CT) using the departmental 
treatment planning software Plan UNC (20) without using any 
other scans to aid in contouring. The primary GTV-CT was 
non-uniformly expanded using clinical judgment to form the 
high-risk primary CTV (for patients in this study, the median 
“minimum” primary CTV expansion was 7 mm, range 4–9 mm). 
The nodal GTV-CT was uniformly expanded by 7 mm to form 
the high-risk nodal CTV. An elective nodal region was contoured 
to form the standard risk CTV. All CTVs were expanded by 
3 mm to form the corresponding planning target volume (PTV). 
All patients were treated using these CT-based volumes with 
intensity-modulated radiation therapy, using the Tomotherapy 
(R) Treatment Planning System (Accuray Inc., Sunnyvale, CA, 
USA) for nine patients and conventional linear accelerators for 
two patients (one on a Siemens Oncor and one on a Siemens 
Artiste, treatments planned using Plan UNC). Dosimetric cal-
culations were performed using Tomotherapy-specific software 
for the patients treated on Tomotherapy, and Plan UNC for 
patients treated on conventional linear accelerators. Patients were 
treated using a simultaneous integrated boost technique to two 
prescribed dose levels: the high-risk and standard risk regions 
described above. Prescribed radiation dose to the high-risk 
volume was 60 or 70 Gy (2 Gy per fraction, seven patients were 
enrolled on an institutional de-intensification trial and received 
60 Gy). Prescribed radiation dose to the standard risk volume was 
54 Gy (1.8 Gy per fraction for patients prescribed 60 Gy to the 
high-risk volume, and 1.54 Gy per fraction for patients prescribed 
70 Gy to the high-risk volume).
gTV-PeT/Mri Delineation
Following treatment of patients using CT-based volumes and 
plans, a post hoc analysis was performed using PET/MRI. PET/
MRI scans were obtained pretreatment but were not used pro-
spectively and did not influence radiation treatment planning. 
Primary and nodal volumes were delineated on PET/MRI (GTV-
PET/MRI) using MIM Vista (MIM Software Inc., Cleveland, OH, 
USA). The GTV-PET/MRI was the union of a MRI-based and 
PET-based GTV. The MRI-based GTV was delineated manually 
using both contrast-enhanced T1 sequences and T2 sequences. 
The PET-based GTV was delineated using the MIM Vista PET 
Edge detection tool, which is a gradient-based method that has 
been previously described (21). The GTV-PET/MRI was deline-
ated by the treating radiation oncologist and a single neuroradi-
ologist without comparison to GTV-CT.
Volumetric evaluation
Volumetric evaluations were performed using MIM Vista and 
examined spatial and positional differences between GTV-CT 
and GTV-PET/MRI. Planning CT-based target contours and 
dose grids from each patient’s actual radiation treatment were 
exported to MIM Vista. PET/MRI scans were registered to the 
planning CT using the MIM Vista rigid registration tool per 
the technique as described by Hwang et  al., where separate 
rigid registrations are manually performed for the primary as 
well as each nodal GTV “area of interest” using the closest 
anatomical landmarks for each instance. For our primarily 
oropharyngeal cancer patients, the landmarks most commonly 
used were the mandible, hyoid, vertebrae, enhancing blood 
vessels, and the tumor itself, if visible. In the Hwang study, 
this rigid registration process was found to have an error of 
roughly 4 mm for tumor volumes, as assessed using the COM 
(distance between calculated centers of mass for two volumes) 
method (22).
The volumes and intersection of both primary and nodal 
GTV-CT and GTV-PET/MRI contours were then recorded to 
calculate the Dice similarity coefficient (DSC), a validated metric 
to evaluate spatial overlap between two volumes. The DSC is 
calculated using the equation: 2 ×  (A ∩  B)/(A +  B), where A 
and B represent two volumes, (A ∩ B) represents the volume of 
intersection, and (A +  B) represents the absolute sum of their 
volumes. A DSC ≥0.7 has been reported as a “good” overlap by 
some investigators (23), but DSC may also vary with changes 
in the size of the compared volumes. In addition, the modified 
Hausdorff distance (mHD) (24) was calculated for each GTV-CT 
and corresponding GTV-PET/MRI contour. The mHD measures 
the similarity between two volumes by reporting the mean 
orthogonal distance between surface points. A smaller value sug-
gests a lower “distance” and, therefore, greater similarity between 
the compared volumes.
Dosimetric evaluation
Dosimetric evaluation was performed using MIM Vista. As dis-
cussed above, GTV-CT was used in treatment planning, whereas 
GTV-PET/MRI was delineated for research purposes only. The 
purpose of the dosimetric evaluation was to assess the clinical 
significance of any volumetric differences; does a treatment plan 
created using GTVs delineated on CT only (as is standard at 
many institutions) potentially underdose GTVs as delineated on 
PET/MRI? For both primary and nodal tumor volumes, doses 
for the registered GTV-PET/MRI and GTV-CT were calculated, 
including the minimum dose delivered to the entire GTV (D100) 
and the minimum dose delivered to 95% of the GTV (D95), 
representing the “hottest” 95% of the GTV. Figure  1 depicts 
examples of GTV delineation, dose coverage, and assessment 
of spatial overlap between planning CT and PET/MRI for two 
patients.
statistical considerations
Statistical analyses were performed using IBM SPSS Statistics for 
Windows, Version 21.0 (IBM Corp., Armonk, NY, USA). Non-
parametric paired-sample Wilcoxon signed-rank test was used 
to compare GTV size and dose received by CT vs. PET/MRI-
generated volumes, with a two-sided p value <0.05 considered 
statistically significant.
resUlTs
Patient characteristics are summarized in Table 1. There were 11 
patients who received both a pretreatment planning CT and PET/
Table 1 | Patient characteristics (n = 11).
Primary tumor site
Tonsil 7 (64%)
Base of tongue 3 (27%)
Larynx 1 (9%)
T-stage
T1 2 (18%)
T2 7 (64%)
T3 1 (9%)
T4 1 (9%)
n-stage
N0 3 (27%)
N1 1 (9%)
N2b 6 (55%)
N2c 1 (9%)
Prescribed radiation dose
70 Gy 4 (36%)
60 Gy 7 (64%)
Unilateral vs. bilateral neck radiation
Unilateral 3 (27%)
Bilateral 8 (73%)
FigUre 1 | example of computed tomography (cT) vs. PeT/Mri gTV 
delineation. Primary tumor and nodal GTVs for two different patients (a,b) 
are shown delineated using CT (blue outline) and PET/MRI (red outline). The 
95% prescription isodose line from their CT-based treatment plan is 
overlayed (white, shaded). The patient in panel (a) (axial representation) had 
fair spatial overlap between PET/MRI and CT volumes, with a Dice similarity 
coefficient (DSC) of 0.72 for the primary GTV and 0.69 for the nodal GTV. The 
patient in panel (b) (coronal representation) had relatively poor spatial overlap 
between the PET/MRI and CT nodal volumes, with a DSC of only 0.48. 
Clinical target volume and planning target volume expansions are not shown.
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MRI and were evaluable. PET/MRI was performed on the same 
day as planning CT for six patients and within 5 days of plan-
ning CT for the remaining five patients. No stage migration was 
observed. Ten patients had primary oropharyngeal carcinoma 
and one patient had laryngeal carcinoma. Ten patients received 
chemoradiation and one patient received radiation alone. Of the 
11 enrolled patients, 9 patients had evaluable primary GTVs (2 
patients had unknown primary) and 7 patients had evaluable 
nodal GTVs (4 patients had node-negative disease).
Results of the volumetric assessment of PET/MRI vs. planning 
CT-generated GTVs are shown in Table 2. Overall, GTVs gener-
ated by both imaging modalities were similar in size, with mean 
primary GTV of 13.2 and 14.3 cc (p = 0.82) and mean nodal GTV 
of 19.0 and 23.0 cc (p = 0.94), for CT and PET/MRI, respectively. 
However, there were individual cases with larger volumetric dif-
ferences due to the improved visualization of gross tumor with 
PET/MRI (e.g., patients 7 and 11, Figure 2). There was some spa-
tial discrepancy between the locations of the CT and PET/MRI 
volumes, with mean intersection of only 8.7 cc for primary and 
14.4 cc for nodal tumors. The mean DSC between PET/MRI and 
CT was 0.63 (SD 0.11) for primary tumor volumes and 0.69 (SD 
0.10) for nodal tumor volumes. Results of the mHD calculations 
are shown in Table 3. The mean mHD was 1.6 mm (SD 0.7 mm) 
between PET/MRI and planning CT primary tumor volumes and 
2.3 mm (SD 1.5 mm) between nodal tumor volumes.
Results of the dosimetric evaluation are shown in Table 4. The 
small overlap discrepancy and small mHD between GTV-CT and 
GTV-PET/MRI did not appear to lead to potential underdosing 
of the GTV-PET/MRI based on treatment plans generated using 
planning CT alone. For both primary and nodal tumors, D100 
and D95 were close to prescription dose and not significantly 
different between CT vs. PET/MRI-generated GTVs for each 
patient and on average. The D95 was very similar between CT and 
PET/MRI-generated GTVs, regardless of whether they received a 
prescription RT dose of 60 or 70 Gy.
DiscUssiOn
We assessed volumetric differences in GTVs delineated using rou-
tine contrast-enhanced planning CT vs. gadolinium-enhanced 
PET/MRI, as well as differences in dose received by these volumes 
after treatment based on planning CT alone. Overall, the mean 
primary and nodal GTV size for all patients was not significantly 
different between CT and PET/MRI volumes, though there were 
individual cases with larger differences (Figure  2). The use of 
PET/MRI led to volumes that were sometimes somewhat spatially 
discordant from CT volumes, with an average DSC slightly below 
0.7 for both primary and nodal volumes. Furthermore, mean 
orthogonal distance difference as calculated using the modified 
Hausdorff method was low between CT and PET/MRI volumes. 
Given these similar volumes, small discrepancies in spatial 
overlap, and small mean orthogonal distance differences, doses 
received by PET/MRI GTVs were also similar to doses received 
by CT-GTVs based on CT-only treatment plans.
Target delineation for radiotherapy planning is dependent 
on quality of radiologic studies, and there is interest in hybrid 
PET/MRI systems incorporating benefits of both PET and MRI. 
Previous studies that have similarly investigated the usefulness 
of PET/CT for target delineation have shown varied results, 
though most suggest that PET/CT delineation reduces GTV size 
compared to CT alone. In one study, Leclerc et al. showed that 
PET-based contours were smaller and resulted in significantly 
lower parotid and oral cavity doses (12). Guido et al. also showed 
smaller GTV size with PET/CT vs. CT planning (11). However, 
FigUre 2 | Two different patients [(a), patient 7, and (b), patient 11] where PeT/Mri substantially altered the primary gTV. Scans from left to right are 
the planning computed tomography (CT) scan (GTV-CT shown in red), magnetic resonance imaging (MRI) component of PET/MRI, and fused PET/MRI (GTV-PET/
MRI shown in blue). Patient 7 (a) had a left tonsil primary. PET/MRI showed soft tissue encroachment to the uvula not delineated on CT, with a resultant increase in 
GTV size. Patient 11 (b) had a base of tongue primary. Though the planning CT-GTV included indeterminate soft tissue in the right base of tongue, PET/MRI showed 
tumor limited to the central base of tongue, with a resultant decrease in GTV size.
Table 2 | Volumetric comparison of computed tomography vs. PeT/Mri gTVs.
Primary tumor volume (cc) nodal tumor volume (cc)
Pt. gTV-cT gTV-PeT/Mri intersection Dsc gTV-cT gTV-PeT/Mri intersection Dsc
1 23.6 22.1 12.2 0.53 – – – –
2 – – – – 19.1 20.4 15.0 0.76
3 – – – – 12.0 17.4 9.9 0.67
4 3.9 7.3 3.1 0.55 10.3 8.6 4.5 0.48
5 15.0 14.1 10.9 0.75 – – – –
6 22.1 28.1 17.5 0.70 25.7 23.9 18.5 0.75
7 19.6 28.8 15.7 0.65 4.6 4.3 3.1 0.70
8 6.4 6.3 4.6 0.72 50.2 77.1 44.1 0.69
9 7.8 8.3 5.0 0.62 – – – –
10 10.8 9.5 6.9 0.68 – – – –
11 10.0 4.1 2.8 0.40 11.5 9.4 5.7 0.55
Mean (SD) 13.2 14.3 8.7 0.63 (0.11) 19.0 23.0 14.4 0.69 (0.10)
GTV, gross tumor volume; DSC, dice similarity coefficient.
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Paulino et al. showed that volumes were larger in 18% of patients 
using PET/CT delineation, which resulted in underdosing of 
PET/CT-GTVs based on the CT-GTV radiation plan (13). To the 
authors’ knowledge, there are no similar studies comparing PET/
MRI vs. CT planning, which was the impetus for this pilot study. 
Here, we report that in a predominantly oropharyngeal cancer 
patient population, PET/MRI and CT-GTVs were volumetrically 
and dosimetrically (based on CT planning) similar.
Regardless of any observed changes to the GTV using PET 
delineation, a larger question is whether any difference (between 
tumor delineation using CT vs. PET or any other imaging modality) 
is clinically significant. In our dosimetric analysis, we attempted 
to answer this question by assessing whether CT-generated treat-
ment plans would have underdosed gross tumor as delineated on 
PET/MRI, which would have potentially important implications. 
We found that dosimetric coverage was not substantially differ-
ent between PET/MRI and CT-based volumes, regardless of the 
degree of volumetric agreement. Similarly, in a previous report 
from our institution on 91 patients with head and neck cancer, 
GTVs based on pretreatment PET/CT scans were generated and 
Table 4 | Dosimetric comparison of computed tomography vs. PeT/Mri gTVs.
Pt. Prescribed 
dose (gy)
Primary tumor dose (gy) nodal tumor dose (gy)
D100  
gTV-cT
D100  
gTV-PeT/Mri
D95  
gTV-cT
D95  
gTV-PeT/Mri
D100  
gTV-cT
D100  
gTV-PeT/Mri
D95  
gTV-cT
D95  
gTV-PeT/Mri
1 70 70.8 65.8 71.1 71.1 – – – –
2 60 – – – – 60.8 60.8 61.4 61.4
3 60 – – – – 60.5 60.3 61.2 61.1
4 60 60.5 58.5 61.0 60.3 60.7 56.7 61.0 60.7
5 70 70.5 70.5 70.9 70.9 – – – –
6 60 59.6 59.6 60.2 60.2 60.0 60.0 60.4 60.4
7 70 71.0 70.4 71.4 71.3 70.5 70.6 71.1 71.2
8 60 60.3 60.1 60.8 60.7 59.9 54.7 60.8 60.6
9 70 70.9 70.5 71.2 71.2 – – – –
10 60 60.3 60.4 60.7 60.8 – – – –
11 60 59.8 59.9 60.2 60.2 60.0 59.9 60.3 60.3
Mean 63.6 64.8 64.0 65.3 65.2 61.8 60.4 62.3 62.3
GTV, gross tumor volume; D100, dose received by 100% of the GTV; D95, dose received by 95% of the GTV.
Table 3 | Modified hausdorff Distances for computed tomography vs. 
PeT/Mri gTVs.
Pt. Primary tumor (mm) nodal tumor (s) (mm)
1 1.3 –
2 – 0.8
3 – 1.4
4 2.0 2.7
5 1.6 –
6 1.2 2.1
7 2.6 5.3
8 1.1 2.5
9 1.1 –
10 1.0 –
11 2.7 1.5
Mean (SD) 1.6 (0.7) 2.3 (1.5)
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registered to their CT-based treatment plans. There was no differ-
ence in radiation dose to PET/CT vs. CT-GTVs, even in patients 
who later developed local recurrence (25). These findings are 
most likely a reflection of CTV and PTV expansions. Regardless 
of small changes in GTV size, CTV expansions in the range of 
5–10 mm are routinely applied at both the primary and involved 
nodal sites. Furthermore, an even larger region of “standard risk” 
CTV that covers uninvolved at-risk neck nodal levels is prescribed 
doses in the range of 50–60 Gy, and additional PTV margins of 
3–5 mm are routinely added to each CTV.
Given that the mHD was only around 2 mm between PET/
MRI and CT-GTVs in our study, any volumetric differences 
are likely to be masked by these expansions in terms of actual 
dose received. In another study, Fortunati et al. also investigated 
spatial and positional differences between registered head and 
neck volumes delineated on CT vs. MRI. Though their study 
examined normal tissue structures rather than tumor volumes, 
they reported a mean mHD of 1.7 mm, similar to our findings 
(26). Fleckenstein et  al. compared lung cancer tumor volumes 
delineated on diffusion-weighted MRI registered to tumor 
volumes delineated using PET/CT and report a similar “average” 
Hausdorff distance of 2.25 mm (27). Furthermore, Commandeur 
et  al. investigated prostate volumes delineated on MRI vs. CT 
and report a Hausdorff distance of around 3 mm (28). Taken as 
a whole, these small Hausdorff distances suggest that the benefit 
of alternate imaging modalities for gross tumor delineation may 
be greater in situations where large CTV/PTV margins are not 
routinely used or are limited by critical organs.
Although we do not report a benefit of PET/MRI here, this was 
a pilot study of a new technology, and there are numerous exciting 
aspects (and disease settings) that warrant further investiga-
tion. For instance, we did not examine the impact of PET/MRI 
on subjective CTV expansions, which ranged from 4 to 9 mm 
around the high-risk GTV using planning CT. There were several 
patients in this study where the use of PET/MRI substantially 
altered the GTV, whether increasing or decreasing the volume 
(as demonstrated in Figure  2). It is possible that heightened 
confidence in gross tumor delineation with PET/MRI could lead 
to the use of smaller CTV margins, which could reduce toxicity 
while maintaining confidence in tumor coverage. Furthermore, 
future studies could also investigate whether PET/MRI could 
reduce inter-observer variation in tumor volume delineation, 
which could translate to improved “quality” for head and neck 
cancer treatment.
Future studies on the utility of PET/MRI for tumor deline-
ation may also benefit from incorporation of more advanced 
imaging techniques such as functional MR sequences and novel 
radiotracers. For instance, studies are underway to investigate the 
combination of PET with diffusion-weighted imaging (DWI) and 
MR spectrosocopy for infiltrative brain gliomas (29). In head and 
neck cancer, one area of particular interest is the potential ability 
of functional MRI sequences such as DWI to differentiate benign 
from malignant lymph nodes and thus increase the specificity of 
PET/MRI as compared to PET/CT. In one study, Schouten et al. 
reported that DWI-MRI had a higher specificity for nodal disease 
(93%) as opposed to PET/CT (84%) (9). In contrast, Queiroz 
et al. assessed the predictive value of DWI as part of PET/MRI 
staging in 70 patients and were unable to detect a difference in 
DWI parameters between benign and malignant lesions (30). 
Though further research is needed, if PET/MRI improves the 
“positive predictive value” for nodal disease, this could have 
major implications on treatment (patient selection, tumor, and 
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CTV delineation) and follow-up (selection of patients for salvage 
surgery vs. continued surveillance). Another interesting avenue 
of research is the incorporation of new PET tracers with hybrid 
PET/MRI. Navarria et  al. used Carbon-11-labeled methionine 
(11C-MET) PET/MRI in 69 patients with high grade glioma. 
Whereas 50% of failures were outside the T1 post-contrast vol-
ume, all failures would have been encompassed within a “biologic 
tumor volume” generated by use of the 11C-MET uptake regions 
(31). Furthermore, the use of novel radiotracers in combina-
tion with functional MRI sequences may be useful to assess 
intra-treatment (e.g., aiding in adaptive radiation planning) and 
posttreatment response.
A major limitation of the present study is the rigid registra-
tion process, which is expected to introduce some degree of 
error in the assessment of differences between PET/MRI and 
CT contours. In addition, PET/MRI scans were not specified to 
be completed in the treatment position, which may increase the 
inherent error when performing image registrations. We origi-
nally intended to use deformable registration, but we found that 
the deformable registration performance of MIM Vista Software 
when registering two different image modalities (e.g., MR to CT 
as in this study) was suboptimal. Therefore, we opted to use mul-
tiple rigid body registration. As newer deformable registration 
technology becomes available, it may become more feasible to 
perform cross modality (e.g., MRI to CT) deformable registration 
for comparison of tumor volumes. Also, the necessity of CT for 
radiation dose calculations and, therefore, PET/MRI registration 
is a significant challenge in the implementation of this technol-
ogy for radiotherapy planning, though MRI planning is an area 
of current research interest (in contrast to PET/CT simulators, 
which are already in routine use). Furthermore, the longer image 
acquisition time of MRI may also introduce motion artifact and 
increase delineation error, though this limitation applies to most 
studies using this modality. Another limitation is that we did 
not assess intra or inter-observer variation; the same radiation 
oncologist generated the final volumes on both CT and PET/MRI 
(with the aid of a neuroradiologist). The number of patients was 
also limited, and it is possible that with more patients, we could 
have found more individuals in which PET/MRI had a greater 
impact. Our primary objective was to assess differences in GTV 
delineation and dosimetric coverage of this GTV, and we did not 
examine the impact of PET/MRI on CTV expansions (e.g., does 
heightened confidence decrease subjective margins?). Finally, we 
did not examine the impact of functional imaging sequences, 
including DWI-MRI and dynamic contrast-enhanced MRI, 
which could provide additional benefit.
Patients in our study had uncomplicated head and neck can-
cers, and although there were individuals with larger differences, 
our analysis showed that PET/MRI and CT-generated GTVs 
were overall similar volumetrically and received similar radiation 
doses. Further studies in this and other settings are needed to 
determine the optimal use of PET/MRI for treatment planning. 
The usefulness of PET/MRI for tumor delineation may also be 
greater in situations where the tumor is more difficult to delineate 
using standard radiographic studies, including situations such as 
re-irradiation and locations such as base of skull, nasopharynx, 
and paranasal sinuses, where perineural and intracranial exten-
sion are more difficult to ascertain. PET/MRI target delineation 
may also be advantageous for radiosurgery, particle therapy, 
and in locations juxtaposed to critical normal tissue structures, 
where allowable margins are small and dose gradients are very 
sharp. These are clinical situations where even small changes in 
GTV delineation could affect dosimetric coverage and potentially 
clinical outcomes.
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